Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Rhythm Pharmaceuticals, Inc. - Common Stock (NQ:RYTM)

101.74 +1.08 (+1.07%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 468,185
Open 100.87
Bid (Size) 95.00 (100)
Ask (Size) 125.00 (100)
Prev. Close 100.66
Today's Range 98.52 - 103.78
52wk Range 45.91 - 116.00
Shares Outstanding 66,684,077
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
These stocks are moving in today's after hours session ↗
The regular session of the US market on Tuesday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements. 
Via Chartmill
News headline image
Rhythm Pharmaceuticals Announces Presentation of Four Datasets at ObesityWeek® 2025
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire

Performance

YTD
+69.4%
+69.4%
1 Month
-6.8%
-6.8%
3 Month
-1.5%
-1.5%
6 Month
+63.1%
+63.1%
1 Year
+72.4%
+72.4%

More News

Read More
News headline image
Rythm Pharmaceuticals' (RYTM) Chief Technical Officer Sells 9,748 Shares for $1.1 Million ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Rhythm Pharmaceuticals Announces FDA Extension of Review Period for IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For November 4, 2025 ↗
Via Benzinga
News headline image
Rhythm Pharmaceuticals's Earnings: A Preview ↗
Via Benzinga
News headline image
Rhythm Pharmaceuticals Announces Public Reimbursement for IMCIVREE® (setmelanotide) in Canada in Five Provinces and Under the Federal Non-Insured Health Benefits Program
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals (NASDAQ:RYTM) Reports Mixed Q3 2025 Results ↗
Via Chartmill
News headline image
Rhythm Pharmaceuticals Reports Third Quarter 2025 Financial Results and Business Update
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For August 5, 2025 ↗
Via Benzinga
News headline image
Curious about the stocks that are showing activity after the closing bell on Monday? ↗
Via Chartmill
News headline image
Rhythm Pharmaceuticals to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
2 Under-the-Radar Stocks That Could Soar ↗
Via The Motley Fool
News headline image
Peering Into Rhythm Pharmaceuticals's Recent Short Interest ↗
Via Benzinga
News headline image
Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals Announces FDA Acceptance of sNDA for Setmelanotide in Acquired Hypothalamic Obesity
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
12 Analysts Have This To Say About Rhythm Pharmaceuticals ↗
Via Benzinga
News headline image
Rhythm (RYTM) Q2 Revenue Jumps 67% ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) Reports Mixed Q2 2025 Earnings: Revenue Beat Overshadowed by Wider Losses ↗
Via Chartmill
News headline image
Rhythm Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Update
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals to Report Second Quarter 2025 Financial Results on Tuesday, August 5, 2025
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Should You Invest in This Under-the-Radar Weight Loss Stock? ↗
Via The Motley Fool
News headline image
A Glimpse Into The Expert Outlook On Rhythm Pharmaceuticals Through 10 Analysts ↗
Via Benzinga
News headline image
Rhythm Pharmaceuticals CFO Sells 42,120 Shares ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Rhythm Pharmaceuticals Presents Data on MC4R Agonists Setmelanotide and Bivamelagon at ENDO 2025
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Rhythm Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Rhythm Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Rhythm Pharmaceuticals, Inc. - Common Stock trade on?
Rhythm Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Rhythm Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Rhythm Pharmaceuticals, Inc. - Common Stock is RYTM on the Nasdaq Stock Market
What is the current price of Rhythm Pharmaceuticals, Inc. - Common Stock?
The current price of Rhythm Pharmaceuticals, Inc. - Common Stock is 101.74
When was Rhythm Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Rhythm Pharmaceuticals, Inc. - Common Stock was at 11/21/25 04:00 PM ET
What is the market capitalization of Rhythm Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Rhythm Pharmaceuticals, Inc. - Common Stock is 6.78B
How many shares of Rhythm Pharmaceuticals, Inc. - Common Stock are outstanding?
Rhythm Pharmaceuticals, Inc. - Common Stock has 7B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.